ArticleOncogene2025
Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression.
Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- TFAM loss drives oxaliplatin resistance by linking mtDNA release to STING-TBK1-mediated lysophagy.Oncogene · 2026Article
- Zalcitabine induces ferroptosis in multiple myeloma through the TFAM-cGAS-STING-SLC7A11 axis.Journal of translational medicine · 2026Article
- Redox-driven mitochondrial DNA stress in hepatocellular carcinoma: innate immune remodelling, tumour immune escape, and immunotherapy implications.Frontiers in immunology · 2026Review
- Targeting cGAS-STING-macrophage axis: a novel therapeutic horizon for renal fibrosis.Frontiers in immunology · 2026Review
- Intercellular mitochondrial transfer in melanoma progression and therapeutic resistance: mechanisms and targeting potential.Frontiers in oncology · 2026Review
- Mitochondrial fission and fusion in inflammatory diseases: mechanisms and therapeutic implications.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The infiltration of TAMs mediates an immunosuppressive tumor microenvironment, which plays a crucial role in the malignant progression of HCC. TFAM is a key molecule that regulates mtDNA replication and transcription, and its expression frequently downregulated in various tumors, including HCC. Our previous study indicated that the downregulation of TFAM triggers mtDNA stress, thereby inducing autophagy and promoting ESCC survival through the STING pathway. However, it remains unclear whether cytosolic mtDNA stress, mediated by TFAM downregulation, is implicated in microenvironment regulation, particularly in the infiltration of TAMs in HCC. In this study, we found that TFAM expression was significantly decreased and correlated with CD163 expression in HCC tissues. The downregulated expression of TFAM in HCC cells contributed to TAM infiltration. Mechanistically, the downregulation of TFAM induced cytosolic mtDNA stress, which activated the NLRP3 inflammasome and promoted the expression of IL-18 and IL-1β in HCC cells, thereby inducing macrophage recruitment and M2 polarization. Depleting cytosolic mtDNA using DNase I or blocking NLRP3 inflammasome activation with an NLRP3 antagonist in HCC cells with TFAM downregulation significantly suppresses the infiltration of M2-TAMs. Moreover, blocking the mtDNA-NLRP3 pathway significantly inhibited TAM infiltration and orthotopic mouse HCC model progression. Taken together, our results reveal a novel mechanism by which cytosolic mtDNA stress mediates TAM infiltration in HCC.
Indexed as
Identifiers
40517169What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.